TuHURA Biosciences, Inc. (HURA)
1.63
+0.02
(+1.24%)
USD |
NASDAQ |
Nov 06, 16:00
1.66
+0.03
(+1.84%)
After-Hours: 05:08
TuHURA Biosciences Net Income (Quarterly) : -9.223M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -9.223M |
| March 31, 2026 | -7.537M |
| December 31, 2025 | -6.761M |
| September 30, 2025 | -7.102M |
| June 30, 2025 | -9.524M |
| March 31, 2025 | -6.664M |
| December 31, 2024 | -5.996M |
| September 30, 2024 | -5.579M |
| June 30, 2024 | -2.324M |
| March 31, 2024 | -4.842M |
| December 31, 2023 | -1.023M |
| September 30, 2023 | -2.962M |
| June 30, 2023 | -3.335M |
| March 31, 2023 | -3.264M |
| December 31, 2022 | -3.454M |
| September 30, 2022 | -4.596M |
| June 30, 2022 | -5.446M |
| March 31, 2022 | -5.356M |
| December 31, 2021 | -5.893M |
| September 30, 2021 | -5.966M |
| June 30, 2021 | -6.732M |
| March 31, 2021 | -6.635M |
| December 31, 2020 | -5.413M |
| September 30, 2020 | -19.52M |
| June 30, 2020 | -3.823M |
| Date | Value |
|---|---|
| March 31, 2020 | -1.957M |
| December 31, 2019 | -1.740M |
| September 30, 2019 | -1.606M |
| June 30, 2019 | -2.583M |
| March 31, 2019 | -1.664M |
| December 31, 2018 | -1.810M |
| September 30, 2018 | -1.992M |
| June 30, 2018 | -2.377M |
| March 31, 2018 | -2.933M |
| December 31, 2017 | -3.162M |
| September 30, 2017 | -2.666M |
| June 30, 2017 | -2.601M |
| March 31, 2017 | -1.868M |
| December 31, 2016 | -1.322M |
| September 30, 2016 | -2.290M |
| June 30, 2016 | -3.456M |
| March 31, 2016 | -1.140M |
| December 31, 2015 | -2.647M |
| September 30, 2015 | -1.621M |
| June 30, 2015 | -0.2995M |
| March 31, 2015 | -2.087M |
| December 31, 2014 | -1.077M |
| September 30, 2014 | -1.517M |
| June 30, 2014 | 3.629M |
| March 31, 2014 | -3.199M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 53.52M |
| Alnylam Pharmaceuticals, Inc. | 2.167B |
| Anika Therapeutics, Inc. | -0.311M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 14.16M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 9.223M |
| EPS Diluted (Quarterly) | -0.1442 |
| Enterprise Value | 107.09M |
| Earnings Yield | -32.72% |
| Normalized Earnings Yield | -34.33 |